bluebird bio Reports Fiscal Second Quarter 2013 Financial Results Read more about bluebird bio Reports Fiscal Second Quarter 2013 Financial Results
bluebird bio to Present at Two Upcoming Conferences Read more about bluebird bio to Present at Two Upcoming Conferences
bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option Read more about bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option
bluebird bio Announces Pricing of Initial Public Offering Read more about bluebird bio Announces Pricing of Initial Public Offering
bluebird bio Announces Global Clinical Plans to Treat Adrenoleukodystrophy (ALD) Read more about bluebird bio Announces Global Clinical Plans to Treat Adrenoleukodystrophy (ALD)
bluebird bio Adrenoleukodystrophy (ALD) Product Recognized in Science Magazine's Scientific Breakthroughs in 2009 Read more about bluebird bio Adrenoleukodystrophy (ALD) Product Recognized in Science Magazine's Scientific Breakthroughs in 2009
bluebird bio Appoints Mitchell Finer, Ph.D. as Chief Scientific Officer Read more about bluebird bio Appoints Mitchell Finer, Ph.D. as Chief Scientific Officer
bluebird bio Secures $35M in Series B Funding Read more about bluebird bio Secures $35M in Series B Funding
New Data From Adrenoleukodystrophy (ALD) Pilot Study Presented at American Society of Gene and Cell Therapy Show Three-Year Disease Stabilization of Patients Read more about New Data From Adrenoleukodystrophy (ALD) Pilot Study Presented at American Society of Gene and Cell Therapy Show Three-Year Disease Stabilization of Patients
Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer Read more about Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer